Streetbeat News

Revenues

FXI

China's Consumer Price Index (CPI) for March decreased by 1%, surpassing the estimated decrease of 0.5% and contrasting with the previous month's increase of 1.0%.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 4:30 am

FXI

China's Consumer Price Index (CPI) for March increased by 0.1% year-over-year, falling short of the estimated 0.4% and the previous month's 0.7%. This indicates a slowdown in inflation within the country.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 4:30 am

FXI

China's Producer Price Index (PPI) for March reported a year-over-year decrease of 2.8%, aligning with estimates but showing a slight decline from the previous -2.7%.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 4:30 am

RCEL

AVITA Medical anticipates its 2024 revenue to be at the lower end of its previously forecasted range of $78.5M-$84.5M, with estimates around $80.093M. The company will release its Q1 2024 financial results after U.S. markets close on May 13, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 9:17 pm

RCEL

AVITA Medical has reduced its Q1 commercial revenue forecast to $11.0-$11.3 million from the previously expected $14.8-$15.6 million, due to a slower-than-expected conversion rate of new accounts for its expanded label of full-thickness skin defects.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 9:14 pm

AEE

Ameren (NYSE:AEE) has received mixed analyst ratings over the past three months, with a recent shift towards a more bearish outlook. The latest ratings include 1 somewhat bullish, 2 indifferent, and 1 bearish. Analysts have adjusted their 12-month price targets, with an average target of $73.75, reflecting a slight increase from the previous average of $72.67. Ameren's financial performance shows a decline in revenue growth by -20.92% for the last quarter of 2023, with a net margin of 9.77%, ROE of 1.41%, and ROA of 0.39%, indicating potential challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 9:01 pm

KIDS

OrthoPediatrics (NASDAQ:KIDS) has received mixed analyst ratings over the last quarter, with a recent shift towards more bullish sentiments. The average 12-month price target has been raised to $36.83 from $34.00, indicating a positive outlook from financial experts. The company has shown a notable revenue growth rate of 21.36% as of December 31, 2023, outperforming peers in the Health Care sector. However, challenges remain with a net margin of -17.79% and an ROA of -1.54%, suggesting areas for improvement in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 9:01 pm

RIOT

14 analysts have recently shared mixed evaluations of Riot Platforms (NASDAQ:RIOT), with a shift towards more bullish sentiments in the past 30 days. The average 12-month price target for RIOT has increased to $18.61, up from $17.80. Analyst actions include both upgrades and downgrades, reflecting a dynamic view on the company's performance and outlook. Riot Platforms, a Bitcoin mining company, has shown significant financial growth, with a revenue increase of 31.03% as of December 31, 2023, and outperforms industry averages in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 9:00 pm

HUBG

Hub Group (NASDAQ:HUBG) has seen varied analyst opinions over the past three months, with recent ratings ranging from bullish to indifferent. The average 12-month price target is now $43.66, down 18.39% from the previous $53.50. Analyst actions include both upgrades and downgrades, reflecting changing market conditions and company performance. Hub Group's financial performance shows a revenue decline of -23.37% over the last quarter, but it outperforms in net margin, ROE, and ROA, with a low debt-to-equity ratio indicating conservative financial management.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 9:00 pm

VITL

Vital Farms (NASDAQ:VITL) received mixed analyst ratings over the past three months, with 4 bullish and 2 indifferent ratings. The average 12-month price target for VITL has been raised to $21.00, up 17.78% from the previous $17.83, with a high estimate of $26.00 and a low of $16.00. Analysts from firms including TD Cowen, DA Davidson, Lake Street, Stifel, and Goldman Sachs have raised their price targets, reflecting a positive outlook on the company's performance. Vital Farms, an ethical food company, has shown strong financial health with a 23.37% revenue growth rate, a net margin of 5.31%, and an ROE of 3.84%, outperforming industry averages.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 9:00 pm